


SEN177

Cat. No.:	HY-136780	
CAS No.:	2117405-13-5	
Molecular Formula:	C ₁₈ H ₁₉ FN ₆	
Molecular Weight:	338.38	
Target:	Amyloid-β	
Pathway:	Neuronal Signaling	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (92.35 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.9553 mL	14.7763 mL	29.5526 mL
5 mM	0.5911 mL	2.9553 mL	5.9105 mL
10 mM	0.2955 mL	1.4776 mL	2.9553 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SEN177 is a potent glutaminyl cyclase (QPCT) inhibitor with an IC₅₀ of 0.013 μM for glutaminyl-peptide cyclotransferase-like (QPCTL). SEN177 has a K_i of 20 nM for human glutaminyl cyclase (hQC). SEN177 greatly reduces the early stages of mutant HTT oligomerisation and reduces the percentage of neurons with Q80 aggregates. SEN177 has the potential for Huntington's disease research^[1].

REFERENCES

- [1]. Meike E W Logtenberg, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. *Nat Med*
- [2]. Cecilia Pozzi, et al. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders. *J Biol Inorg Chem*. 2018 Dec;23(8):1219-1226.
- [3]. Maria Jimenez-Sanchez, et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. *Nat Chem Biol*. 2015 May;11(5):347-354.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA